A Generic Summer Savings Tour: How Did Your State Do? | Association for Accessible Medicines
GRx+Biosims - No-cost FDA workshop limited to first 100 who sign up. Act now!

A Generic Summer Savings Tour: How Did Your State Do?

The 11th edition of the Association for Accessible Medicines' annual Access and Savings Report (see summary) reveals how much money American patients and taxpayers saved in 2018 through competition from generic drugs and biosimilar alternatives to brand-name biologic medicines. The report provides data by state, based on findings by IQVIA. We’re releasing a detailed publication later this summer.

Some notable facts from the state data:

  • The average state saved $5.7 billion from the use of generics in 2018.
  • Generics benefit states with a large Medicare population. The average Medicare generic savings in 2018 was $1.7 billion per state.
  • Generics also benefit states with a large Medicaid population. Generics saved the average state’s Medicaid program $917 million.

 

U.S. Savings Map 2019

 

All 50 states and Washington D.C. are included in the upcoming report. Here’s a three-state highlights tour:

In South Dakota (home state of AAM’s Kristin Murphy), 2018 savings totaled $793 million, which came from $412.3 million for patients with commercial insurance, $254.7 million for Medicare participants, $81 million for Medicaid enrollees and $44.7 million for non-insured patients who paid cash.

In Connecticut (home state of AAM’s Erica Klinger), savings added up to $3.6 billion in 2018, comprising $1.7 billion for patients with commercial insurance, $1 billion for Medicare participants, $744.2 million for Medicaid enrollees and $105.9 million for non-insured patients who paid cash.

In Pennsylvania (my home state), savings came to $13.7 billion in 2018, comprising $6.4 billion for patients with commercial insurance, $4.5 billion for Medicare participants, $2.3 billion for Medicaid enrollees and $406 million for non-insured patients who paid cash.

State Advocacy

 


By Ashlie Van Meter, AAM Senior Director, State Government Affairs

 

 

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.